A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer

BACKGROUND: We evaluated the safety, maximum-tolerated dose (MTD), pharmacokinetics, recommended dose for phase II (P2RD), and preliminary anticancer activity of a combination eribulin and S-1 therapeutic in metastatic breast cancer patients pretreated with anthracycline and taxane. METHOD: Patients...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Cancer
Autors principals: Sakiyama, T, Tsurutani, J, Iwasa, T, Kawakami, H, Nonagase, Y, Yoshida, T, Tanaka, K, Fujisaka, Y, Kurata, T, Komoike, Y, Nishio, K, Nakagawa, K
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2015
Matèries:
Clinical Study
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4453950/
https://ncbi.nlm.nih.gov/pubmed/25654665
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2015.10
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars